FinlandFinland

Vaccine deal

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the worldwide rights to develop and commercialise what will probably be first product designed to simultaneously protect against the two most common causes of acute gastro­enteritis. Financial details were not disclosed. A joint Phase I/II clinical studies is to be initiated this year in Finland. The combined vaccine, named UMN-2003, utilises norovirus GII-4 virus-like particles and a human recombinant rotavirus VP6 protein. These are produced through a baculovirus expression system.

FinlandFinland

19.03.2008

Helsinki/San Diego – A newly discovered plant gene is centrally involved in the regulation of CO2 uptake for photosynthesis and water evaporation in plants. The discovery of the slac-1 gene can aid in the development of...

FinlandFinland

19.02.2008

Turku – In mid-January, the VTT Technical Research Centre of Finland signed a research agreement with Roche Diagnostics GmbH regarding studies of one of the company’s cancer drugs. The research will be conducted by VTT...

FinlandFinland

19.02.2008

Helsinki – The Academy of Finland started its Sustainable Energy Research Programme (SusEn) in January. Running until 2011, the programme aims to generate new and innovative scientific knowledge in energy technology, energy...

FinlandFinland

22.11.2007

Helsinki – The Academy of Finland Research Council for Biosciences and Environment has contributed roughly a30 million to help support research. The academy announced in October that it is now going to fund more projects than...

Finland, Germany, Politics / LawFinland

21.09.2007

Brussels/Berlin/Helsinki – Germany’s and Finnland’s agriculture ministers have announced they would like to expand the current labelling of genetically modified (GM) food to eggs, milk and meat from animals fed with GM crops....

FinlandFinland

11.07.2007

Tampere – The Regea Institute of Regenerative Medicine located at the University of Tampere has received € 144,000 for stem cell research from a private donor who wishes to remain anonymous. The money will provide four years...

FinlandFinland

16.03.2007

Helsinki – In its budget for 2007, the Finnish government has announced an increase in funding for Research and Development by a60 million to a total amount of a1.73 billion. The increases are going to the organisations that...

FinlandFinland

16.03.2007

Helsinki – Under the roof of the Baltic See network ScanBalt a project known as ‘CompetenceRegion’ has now finalized a mapping report to show the life sciences landscape in the 24 Nordic Bioregions represented in ScanBalt....

FinlandFinland

21.11.2006

Helsinki – The Finnish forest-based industry is expecting a growing demand for biomass-based non-food products and the government aims to strengthen research in this area. This was the conclusion being drawn at the “European...

FinlandFinland

21.11.2006

The Academy of Finland and Tekes, the Finnish Funding Agency for Technolgy and Innovation, have together launched the FiDiPro program to bring top researchers from abroad to Finland. The first 24 professors have already been...

Displaying results 31 to 40 out of 96

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/3/article/vaccine-deal.html

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)3.26 SEK5.16%
  • OREXO (S)121.00 SEK4.54%
  • CO.DON (D)2.88 EUR4.35%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • EPIGENOMICS (D)3.06 EUR-8.38%

TOP

  • CELLECTIS (F)13.54 EUR112.6%
  • SANTHERA (CH)68.40 CHF107.3%
  • ADDEX (CH)4.40 CHF101.8%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.98 EUR-50.3%
  • VERONA PHARMA (UK)1.15 GBP-45.2%

TOP

  • SANTHERA (CH)68.40 CHF3009.1%
  • GW PHARMACEUTICALS (UK)439.50 GBP835.1%
  • PAION (D)2.80 EUR324.2%

FLOP

  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events